DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mekinist (Trametinib Dimethyl Sulfoxide) - Current Clinical Trials

 
 



Mekinist Related Clinical Trials

A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST) [Active, not recruiting]

Study for the Evaluation Dabrafenib (Tafinlar) and Trametinib (Mekinist) Plus DNE3 in Patients With Metastatic Melanoma [Terminated]

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer [Active, not recruiting]

A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [Completed]

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction [Recruiting]

Trametinib With GSK2141795 in BRAF Wild-type Melanoma [Active, not recruiting]

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases [Recruiting]

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors [Not yet recruiting]

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma [Completed]

Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Recruiting]

GSK1120212+GSK2141795 for Cervical Cancer [Suspended]

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations [Recruiting]

A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib [Recruiting]

Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer [Recruiting]

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer [Recruiting]

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer [Recruiting]

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma [Not yet recruiting]

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery [Recruiting]

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. [Active, not recruiting]

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma [Not yet recruiting]

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors [Recruiting]

Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Suspended]

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma [Recruiting]

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations [Recruiting]

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer [Active, not recruiting]

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [Active, not recruiting]

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma [Recruiting]

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers [Active, not recruiting]

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors [Recruiting]

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma [Active, not recruiting]

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer [Recruiting]

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia [Recruiting]

A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 [Completed]

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors [Completed]

GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer [Recruiting]

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma [Active, not recruiting]

Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery [Recruiting]

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects [Completed]

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib [Recruiting]

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation [Completed]

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias [Completed]

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous Melanoma [Recruiting]

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. [Terminated]

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [Recruiting]

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma [Recruiting]

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer [Recruiting]

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites [Recruiting]

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma [Active, not recruiting]

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer [Not yet recruiting]

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma [Recruiting]

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel [Completed]

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers [Recruiting]

Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) [Not yet recruiting]

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients [Recruiting]

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer [Not yet recruiting]

Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase [Recruiting]

BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) [Recruiting]

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors [Recruiting]

Safety, Pharmacokinetics (PK) of AKT and MEK Combination [Completed]

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients [Completed]

Combi-Neo Study for Stage IIIB-C and Oligometastatic Stage IV Melanoma [Recruiting]

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 [Completed]

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer [Completed]

GSK1120212 Food-effect Study [Completed]

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib [Not yet recruiting]

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients [Recruiting]

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone [Recruiting]

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor [Completed]

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia [Recruiting]

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer [Withdrawn]

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) [Active, not recruiting]

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 [Recruiting]

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain [Recruiting]

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma [Recruiting]

An Open Protocol for the Compassionate Use of Trametinib [Temporarily not available]

GSK1120212 Rollover Study [Recruiting]

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer [Completed]

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease [Recruiting]

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors [Completed]

Lapatinib Plus Trametinib in KRAS Mutant Malignancies [Recruiting]

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery [Recruiting]

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain [Recruiting]

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma [Active, not recruiting]

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor [Completed]

Radiotherapy & Combi in Metastatic Melanoma [Not yet recruiting]

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) [Recruiting]

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers [Completed]

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma [Recruiting]

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma [Withdrawn]

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma [Recruiting]

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer [Recruiting]

A Study of LY2875358 in Participants With Advanced Cancer [Active, not recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017